Eli Lilly agreed to acquire AtaiBeckley in a deal valued at $2.8 billion upfront, with additional contingent value rights that could increase the total to $3.8 billion. The purchase gives Lilly a toe-hold in psychedelic-based treatment development for mental health conditions, where regulatory pathways have historically been more complex. AtaiBeckley’s lead program, BPL-003 (mebufotenin benzoate), is in late-stage clinical development for treatment-resistant depression, including Phase IIb evidence reported to show symptom reductions beginning on day two. Lilly said the acquisition expands its neuroscience portfolio. Beyond the strategic rationale, the deal reinforces continued big-pharma appetite for nontraditional CNS mechanisms, even as clinical and regulatory uncertainties remain part of the execution risk.